利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.025 秒)

    Stilbene analogs and methods of treating cancer
    2.
    发明授权
    Stilbene analogs and methods of treating cancer 有权
    二苯乙烯类似物和治疗癌症的方法

    公开(公告)号：US08664276B2

    公开(公告)日：2014-03-04

    申请号：US13360109

    申请日：2012-01-27

    申请人： David Watt ,  Chunming Liu ,  Vitaliy M. Sviripa ,  Wen Zhang

    发明人： David Watt ,  Chunming Liu ,  Vitaliy M. Sviripa ,  Wen Zhang

    IPC分类号： A61K31/136 ,  C07C211/45

    CPC分类号： A61K31/03 ,  A61K31/44 ,  C07C39/21 ,  C07C43/23 ,  C07C211/48 ,  C07C211/52 ,  C07C291/04 ,  C07D233/64 ,  C07D295/073 ,  C07D495/04 ,  C09B23/148 ,  G01N33/57484 ,  G01N33/582 ,  G01N2800/52

    摘要： Stilbene analogs and pharmaceutical compositions that are useful for the treatment of various cancers, including without limitation, colorectal cancer (CRC) and breast cancer are disclosed. Such stilbene analogs include, for example, compounds of the following formula: wherein Ra, Rb, R4, R6, R7, R9 and R10 are all H; R2 and R3 are independently H, halo, amino, alkylamino, dialkylamino, N-oxides of dialkylamino, arylalkylamino, trialkylammonium, mercapto, alkylthio, alkanoyl, nitro, nitrosyl, cyano, alkoxy, alkenyloxy, aryl, heteroaryl, sulfonyl, sulfonamide, CONR11R12, NR11CO(R13), NR11COO(R13) or NR11CONR12R13; R11, R12 and R13, are independently, H, alkyl, aryl, heteroaryl or a fluorine; R8 is NRCRdZ wherein Rc is H, alkyl, alkoxy, aryl or heteroaryl, Rd is an alkyl group, Z is a an unshared pair of electrons, H, alkyl or oxygen; and R1 and R5 are halogen.

    摘要翻译： 公开了可用于治疗各种癌症的芪类似物和药物组合物，包括但不限于结肠直肠癌（CRC）和乳腺癌。 这样的1,2-二苯乙烯类似物包括例如下式的化合物：其中R a，R b，R 4，R 6，R 7，R 9和R 10均为H; R2和R3独立地是H，卤素，氨基，烷基氨基，二烷基氨基，二烷基氨基，芳基烷基氨基，三烷基铵，巯基，烷硫基，烷酰基，硝基，亚硝酰基，氰基，烷氧基，烯氧基，芳基，杂芳基，磺酰基，磺酰胺，CONR11R12 ，NR 11 CO（R 13），NR 11 COO（R 13）或NR 11 CONR 12 R 13; R 11，R 12和R 13独立地为H，烷基，芳基，杂芳基或氟; R8是NRCRdZ，其中Rc是H，烷基，烷氧基，芳基或杂芳基，Rd是烷基，Z是未共享的电子对，H，烷基或氧; 并且R 1和R 5是卤素。

    RADIO FREQUENCY IDENTIFICATION TAGS FOR USE IN EXTREME ENVIRONMENTS
    3.
    发明申请
    RADIO FREQUENCY IDENTIFICATION TAGS FOR USE IN EXTREME ENVIRONMENTS 审中-公开
    无线电频率识别标签用于极端环境

    公开(公告)号：US20130057390A1

    公开(公告)日：2013-03-07

    申请号：US13697193

    申请日：2011-05-25

    申请人： David Watt ,  Leon Fay ,  Jose Joseph ,  Karen Marie Nashold ,  David Watters

    发明人： David Watt ,  Leon Fay ,  Jose Joseph ,  Karen Marie Nashold ,  David Watters

    IPC分类号： G06K7/01 ,  G06K19/077 ,  G01K13/00 ,  G06K19/073

    CPC分类号： G06K19/0717

    摘要： A portable RFID (Radio Frequency Identification) tag includes one or more sensors. Each sensor measures a condition of an environment within which the RFID tag is disposed. Circuitry obtains data from measurements provided by each sensor. A transceiver modulates a radio frequency (RF) signal carrying the obtained data. An antenna, electrically coupled to the transceiver, transmits the RF signal. The circuitry, transceiver, and antenna are potted in their entirety in a thermosetting plastic epoxy for purposes of enduring extreme environmental conditions. The one or more sensors can include a temperature probe. A portion of this temperature probe can serve as the antenna.

    摘要翻译： 便携式RFID（射频识别）标签包括一个或多个传感器。 每个传感器测量放置RFID标签的环境条件。 电路从每个传感器提供的测量中获得数据。 收发器调制携带所获得数据的射频（RF）信号。 电耦合到收发器的天线发射RF信号。 电路，收发器和天线全部封装在热固性塑料环氧树脂中，以保持极端的环境条件。 一个或多个传感器可以包括温度探针。 该温度探头的一部分可以用作天线。

    METHOD FOR THE TREATMENT OF ACNE AND CERTAIN DOSAGE FORMS THEREOF
    4.
    发明申请
    METHOD FOR THE TREATMENT OF ACNE AND CERTAIN DOSAGE FORMS THEREOF 有权
    治疗ACNE及其某些剂型的方法

    公开(公告)号：US20100035846A1

    公开(公告)日：2010-02-11

    申请号：US12536359

    申请日：2009-08-05

    申请人： Mitchell Wortzman ,  R. Todd Plott ,  Steven B. Newhard ,  David Watt

    发明人： Mitchell Wortzman ,  R. Todd Plott ,  Steven B. Newhard ,  David Watt

    IPC分类号： A61K31/65

    CPC分类号： A61K31/65 ,  A61K9/2018 ,  A61K9/2054

    摘要： An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9±0.2% hydroxypropoxylated.

    摘要翻译： 口服剂型，包括65mg米诺环素，一定量的乳糖一水合物和一定量的羟丙基甲基纤维素。 羟丙基甲基纤维素是约8.9±0.2％羟丙氧基化的羟丙基甲基纤维素。 口服剂型，包括115毫克米诺环素，一定量的乳糖一水合物和一定量的羟丙基甲基纤维素。 羟丙基甲基纤维素是约8.9±0.2％羟丙氧基化的羟丙基甲基纤维素。

    Adaptive command filtering for servomechanism control systems
    5.
    发明授权
    Adaptive command filtering for servomechanism control systems 有权
    伺服机构控制系统的自适应命令过滤

    公开(公告)号：US07345448B2

    公开(公告)日：2008-03-18

    申请号：US11129059

    申请日：2005-05-12

    申请人： David Watt ,  Mehmet Alpay ,  Mark Unrath ,  John Wen ,  Ben Potsaid

    发明人： David Watt ,  Mehmet Alpay ,  Mark Unrath ,  John Wen ,  Ben Potsaid

    IPC分类号： G05B13/02

    CPC分类号： G05B13/041

    摘要： Preferred embodiments of the invention implement techniques for modifying the command trajectory, the architecture of a servomechanism control system, or both, to reduce the servo error during and/or after the command trajectory. An iterative refinement procedure generates for use by the servomechanism control system a corrective input, du, which significantly reduces the error between the desired and actual servomechanism control system outputs. In one embodiment, a uniquely identified plant model is employed in the iterative refinement procedure to compute an approximate gradient that improves the performance and reliability of the refinement procedure. In another embodiment, the actual plant response is used in place of the identified model in the iterative refinement procedure. This is accomplished by time-reversing the stored error signal from a training run, before applying it to the plant to generate an update to the corrective input signal du.

    摘要翻译： 本发明的优选实施例实现了用于修改命令轨迹，伺服机构控制系统的结构或两者的技术，以减少在命令轨迹期间和/或之后的伺服误差。 对伺服机构控制系统产生的迭代精制过程可用于校正输入du，这显着地减少了期望的和实际的伺服机构控制系统输出之间的误差。 在一个实施例中，在迭代细化过程中采用唯一识别的植物模型来计算提高细化过程的性能和可靠性的近似梯度。 在另一个实施例中，在迭代细化过程中使用实际植物响应来代替所识别的模型。 这是通过将训练运行中存储的误差信号时间反转，然后将其应用到工厂来产生对纠正输入信号du的更新来实现的。

    Test systems or programs
    7.
    发明申请
    Test systems or programs 有权
    测试系统或程序

    公开(公告)号：US20050193263A1

    公开(公告)日：2005-09-01

    申请号：US10512694

    申请日：2004-09-10

    申请人： David Watt

    发明人： David Watt

    IPC分类号： G06F11/36 ,  G06F11/00

    CPC分类号： G06F11/3684 ,  G06F11/321 ,  G06F11/3664 ,  G06F11/3672 ,  G06F11/3688 ,  G06F11/3692

    摘要： Described herein is a method of generating a test program structure from test requirement data. The method comprises translating the test requirement data into a form suitable for execution within a test programming environment to generate a hierarchy of sequence files based on user supplied information. The test program comprises a plurality of Test Blocks and each Test Block comprises at least one Test.

    摘要翻译： 这里描述的是从测试需求数据生成测试程序结构的方法。 该方法包括将测试需求数据转换成适于在测试编程环境内执行的形式，以基于用户提供的信息生成序列文件的层级。 测试程序包括多个测试块，每个测试块包括至少一个测试。

    Method for the treatment of acne and certain dosage forms thereof
    8.
    发明授权
    Method for the treatment of acne and certain dosage forms thereof 有权
    治疗痤疮的方法及其某些剂型

    公开(公告)号：US09192615B2

    公开(公告)日：2015-11-24

    申请号：US12536359

    申请日：2009-08-05

    申请人： Mitchell Wortzman ,  R. Todd Plott ,  Steven B. Newhard ,  David Watt

    发明人： Mitchell Wortzman ,  R. Todd Plott ,  Steven B. Newhard ,  David Watt

    IPC分类号： A61K31/65 ,  A61K9/20

    CPC分类号： A61K31/65 ,  A61K9/2018 ,  A61K9/2054

    摘要： An oral dosage form, including 65 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/−0.2% hydroxypropoxylated. An oral dosage form, including 115 mg of minocycline, an amount of lactose monohydrate, and an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is hydroxypropylmethylcellulose that is about 8.9+/−0.2% hydroxypropoxylated.

    摘要翻译： 口服剂型，包括65mg米诺环素，一定量的乳糖一水合物和一定量的羟丙基甲基纤维素。 羟丙基甲基纤维素是约8.9 +/- 0.2％羟基丙氧基化的羟丙基甲基纤维素。 口服剂型，包括115毫克米诺环素，一定量的乳糖一水合物和一定量的羟丙基甲基纤维素。 羟丙基甲基纤维素是约8.9 +/- 0.2％羟基丙氧基化的羟丙基甲基纤维素。

    Extended-release minocycline dosage forms
    9.
    发明授权
    Extended-release minocycline dosage forms 有权
    延长释放米诺环素剂型

    公开(公告)号：US08722650B1

    公开(公告)日：2014-05-13

    申请号：US12861424

    申请日：2010-08-23

    申请人： Mitchell Wortzman ,  R. Todd Plott ,  Steven B. Newhard ,  David Watt

    发明人： Mitchell Wortzman ,  R. Todd Plott ,  Steven B. Newhard ,  David Watt

    IPC分类号： A61K9/16 ,  A61K9/50 ,  A61K9/52 ,  A61K9/54 ,  A61K31/65

    CPC分类号： A61K31/65

    摘要： An oral dosage form has the following: an amount of minocycline selected from the group consisting of 55 mg, 80 mg, and 105 mg; an amount of lactose monohydrate; an amount of hydroxypropylmethylcellulose. The hydroxypropylmethylcellulose is at least 8.3 to about 9.8% hydroxypropoxylated. The minocycline in the oral dosage form has a dissolution profile or release rates about 35% to about 50% in 1 hour, about 60% to about 75% in 2 hours, and at least about 90% in 4 hours. There is also provided a method of treating acne in a human and a method of assisting a physician in prescribing a dose of minocycline for the treatment of acne.

    摘要翻译： 口服剂型如下：一种选自55mg，80mg和105mg的米诺环素的量; 一定量的乳糖一水合物; 一定量的羟丙基甲基纤维素。 羟丙基甲基纤维素至少为8.3至9.8％羟基丙氧基化。 口服剂型中的米诺环素在1小时内具有约35％至约50％，2小时内约60％至约75％，4小时内至少约90％的释放速率。 还提供了治疗人类痤疮的方法和辅助医生处方剂量的米诺环素用于治疗痤疮的方法。